Gmp development and preclinical validation of car-t cells targeting a lytic ebv antigen for therapy of ebv-associated malignancies

HIGHLIGHTS

• who: Xi Zhang and colleagues from the Arcellx Inc, United States University of Arizona, United States have published the research: GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies, in the Journal: (JOURNAL)
• what: The authors show that gp350CAR-T_cells manufacturing can be up-scaled to yield sufficient cell numbers and high purity for clinical use. The authors demonstrate in_vitro potency of the preclinical gp350CAR-T_cells using different types of gp350+ tumor targets.
• how: These data showed that gp350CAR-T_cells incorporating the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.